Bioequivalence and Bioavailability Forum

Dear All,

I missed this abstract published during PAGE meeting: Validation of non-compartmental analysis (NCA) and bioequivalence results of PKanalix with respect to Phoenix WinNonLin and SAS.

Most interesting here is the set of the datasets they are using:

References:
[1] Schütz et al. “Reference Datasets for 2-Treatment , 2-Sequence , 2-Period Bioequivalence Studies.”, AAPS J. 16, 1292–1297 (2014).
[2] Fuglsang et al. “Reference Datasets for Bioequivalence Trials in a Two-Group Parallel Design.”, AAPS J. 17, 400–404 (2015).

Looks like that sets become to be state of the art!